NEVVI Medicare utilization intelligence

← back

ANGITAPALLI, REVATHIM.D. NPI 1497921829 Clinician

Hematology-Oncology · ARLINGTON, TX

Specialty Hematology-Oncology — from billed Medicare claims
In practice about 26 years since medical school (class of 2000, self-reported to CMS)
Location ARLINGTON, TX · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 30 codes billed · 67,579 disclosed services (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20192026

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2025-02

Year: 2024 · 2023 · 2022 locked column · 2021 locked column · 2020 locked column

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were premium in CY2024. Unlock to see the figure.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services locked column Beneficiary-episodes locked column Avg charge locked column Avg Medicare payment locked column
J1439 Injection, ferric carboxymaltose, 1 mg premiumpremium premiumpremium
J1453 Injection, fosaprepitant, 1 mg premiumpremium premiumpremium
J0897 Injection, denosumab, 1 mg premiumpremium premiumpremium
J1100 Injection, dexamethasone sodium phosphate, 1 mg premiumpremium premiumpremium
J2469 Injection, palonosetron hcl, 25 mcg premiumpremium premiumpremium
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more premiumpremium premiumpremium
96375 Injection of additional new drug or substance into vein premiumpremium premiumpremium
96413 Administration of chemotherapy into vein, 1 hour or less premiumpremium premiumpremium
J3489 Injection, zoledronic acid, 1 mg premiumpremium premiumpremium
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more premiumpremium premiumpremium
96372 Injection of drug or substance under skin or into muscle premiumpremium premiumpremium
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less premiumpremium premiumpremium
J3315 Injection, triptorelin pamoate, 3.75 mg premiumpremium premiumpremium
J1200 Injection, diphenhydramine hcl, up to 50 mg premiumpremium premiumpremium
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less premiumpremium premiumpremium
99426 Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month premiumpremium premiumpremium
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more premiumpremium premiumpremium
96415 Administration of chemotherapy into vein, each additional hour premiumpremium premiumpremium
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle premiumpremium premiumpremium
71260 Ct scan of chest with contrast premiumpremium premiumpremium
96417 Administration of additional new drug or substance into vein, 1 hour or less premiumpremium premiumpremium
80053 Blood test, comprehensive group of blood chemicals premiumpremium premiumpremium
74177 Ct scan of abdomen and pelvis with contrast premiumpremium premiumpremium
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's premiumpremium premiumpremium
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more premiumpremium premiumpremium
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more premiumpremium premiumpremium
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes premiumpremium premiumpremium
99195 Drawing of blood for a medical problem premiumpremium premiumpremium
36415 Insertion of needle into vein for collection of blood sample premiumpremium premiumpremium
78815 Nuclear medicine study from skull base to mid-thigh with ct scan premiumpremium premiumpremium

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.